Genomic Vision is a publicly-traded company on the Euronext regulated market in Paris
GENOMIC VISION SIGNS A DISTRIBUTION AGREEMENT WITH AMCARE GENOMICS LABORATORY IN CHINA FOR ITS FSHD DIAGNOSTIC ASSAY
The company accelerates its strategic development in China, the largest market in the world with 70.000 to 140.000 people suffering from Facioscapulohumeral muscular dystrophy
Bagneux (France), Guangzhou (China), October 19, 2017 – 7.30 am (CEST) – Genomic Vision (FR0011799907 – GV), a company specialized in the development of diagnostic tests for the early detection of cancers and hereditary diseases, and applications for life sciences research, today announced that it has signed an exclusive distribution agreement with AmCare Genomics Laboratory to market the FSHD diagnostic assay in China.
“We are thrilled to have acquired Genomic Vision’s technology and signed an exclusive distribution agreement for the FSHD diagnostic assay in China. Thanks to our large network and connections within the neurology and FSHD communities in China, we are confident in raising significant awareness among physicians and patients on the most powerful diagnostic test for FSHD”, commented Dr. Victor Wei Zhang, CEO of AmCare Genomics Laboratory.
“Following our distribution deal with APG Bio Ltd last June, this marketing agreement with AmCare represents a second major milestone in our global strategy to enter new markets in Asia. In China, it is estimated that 70,000 to 140,000 people are affected with FSHD. Moreover, the field of genomics and genetic testing is extremely developed, notably in large cities. We are convinced that our robust diagnostic technology will provide great benefits to families and patients. We look forward to deploying our FSHD solution in China and to strengthening our presence in the country through this valuable partnership”, added David Del Bourgo, Marketing & Sales Director of Genomic Vision.
Facioscapulohumeral muscular dystrophy (FSHD) is the third most prevalent muscular hereditary myopathy worldwide. This genetic disease manifests as atrophy and weakness in the face, shoulders, and ambulatory muscles. There is great variability in clinical severity, from a severe infantile form to individuals who remain asymptomatic throughout their lives. This autosomal dominant disease is thought to affect 1 in 10,000 to 1 in 20,000 people. The actual number of individuals with FSHD worldwide is 870,000, which could be significantly higher due to undiagnosed cases. About 70% of FSHD patients inherit the disease from a parent, while 30% of the cases are sporadic and associated to de novo mutations.
ABOUT GENOMIC VISION
GENOMIC VISION is a company specialized in the development of diagnostic solutions for the early detection of cancers and serious genetic diseases and tools for life sciences research. Through the DNA Molecular Combing, a strong proprietary technology allowing the identification of genetic abnormalities, GENOMIC VISION supports the R&D productivity of pharmaceutical companies, leaders in the diagnostic industry and research labs.
The Company develops a strong portfolio of diagnostic tests (breast and colorectal cancers, myopathies) and analysis tools (DNA replication, biomarkers discovery, gene editing quality control). Based in Bagneux, near Paris, the Company employs approximately 60 people. GENOMIC VISION is a public company listed on compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR0011799907). For further information, please visit www.genomicvision.com
Co-fondateur et Président du Directoire
Tél. : +33 1 49 08 07 50
Tel. : +33 1 83 62 34 84
Dušan Orešanský / Emmanuel Huynh
Tel. : +33 1 44 71 94 92
Membre des indices CAC® Mid & Small et CAC® All-Tradable
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business.
Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the “Risk Factors” section in its Document de Reference filed with the French Autorité des Marchés Financiers (AMF) on March 28, 2017, under number R.17-009, available on the web site of Genomic Vision (www.genomicvision.com) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.
This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.